Earlier this month, Dr. Joseph Saba joined the “Priorities and Challenges in Polish and European Drug Policy 2025” Conference to share insights on advancing access to medicines in a world shaped by growing discord and policy uncertainty.
- “Me-first” trade policies could unravel decades of progress on medicine access.
- As geopolitical and trade pressures reshape medicine pricing systems, patient-level affordability assessments, not just country, will be increasingly important to ensure that access to treatment solutions remain sustainable and patients are not left behind.
- Ultimately, sustainable access requires policy approaches that balance innovation, affordability, and the realities of healthcare delivery so that advances in medicine can translate into meaningful patient benefit.
